ADVAIR HFA Drug Patent Profile

When do Advair Hfa patents expire, and what generic alternatives are available?

Advair Hfa is a drug marketed by Glaxo Grp Ltd and is included in one NDA.

The generic ingredient in ADVAIR HFA is fluticasone propionate; salmeterol xinafoate. There are twenty-nine drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the fluticasone propionate; salmeterol xinafoate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Advair Hfa

A generic version of ADVAIR HFA was approved as fluticasone propionate; salmeterol xinafoate by HIKMA on December 17^th, 2020.

Summary for ADVAIR HFA

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	7
Clinical Trials:	84
Drug Prices:	Drug price information for ADVAIR HFA
Drug Sales Revenues:	Drug sales revenues for ADVAIR HFA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ADVAIR HFA
What excipients (inactive ingredients) are in ADVAIR HFA?	ADVAIR HFA excipients list
DailyMed Link:	ADVAIR HFA at DailyMed

See drug prices for ADVAIR HFA

See drug sales revenues for ADVAIR HFA

Recent Clinical Trials for ADVAIR HFA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
United States Department of Defense	Phase 1/Phase 2
University of Colorado, Denver	Phase 1/Phase 2
Becro Ltd.	Phase 3

See all ADVAIR HFA clinical trials

Pharmacology for ADVAIR HFA

Drug Class	Corticosteroid beta2-Adrenergic Agonist
Mechanism of Action	Adrenergic beta2-Agonists Corticosteroid Hormone Receptor Agonists

US Patents and Regulatory Information for ADVAIR HFA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxo Grp Ltd	ADVAIR HFA	fluticasone propionate; salmeterol xinafoate	AEROSOL, METERED;INHALATION	021254-001	Jun 8, 2006		RX	Yes	Yes
Glaxo Grp Ltd	ADVAIR HFA	fluticasone propionate; salmeterol xinafoate	AEROSOL, METERED;INHALATION	021254-002	Jun 8, 2006		RX	Yes	Yes
Glaxo Grp Ltd	ADVAIR HFA	fluticasone propionate; salmeterol xinafoate	AEROSOL, METERED;INHALATION	021254-003	Jun 8, 2006		RX	Yes	Yes

Expired US Patents for ADVAIR HFA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxo Grp Ltd	ADVAIR HFA	fluticasone propionate; salmeterol xinafoate	AEROSOL, METERED;INHALATION	021254-003	Jun 8, 2006
Glaxo Grp Ltd	ADVAIR HFA	fluticasone propionate; salmeterol xinafoate	AEROSOL, METERED;INHALATION	021254-001	Jun 8, 2006
Glaxo Grp Ltd	ADVAIR HFA	fluticasone propionate; salmeterol xinafoate	AEROSOL, METERED;INHALATION	021254-001	Jun 8, 2006
Glaxo Grp Ltd	ADVAIR HFA	fluticasone propionate; salmeterol xinafoate	AEROSOL, METERED;INHALATION	021254-003	Jun 8, 2006

EU/EMA Drug Approvals for ADVAIR HFA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Teva B.V.	Airexar Spiromax	salmeterol xinafoate, fluticasone propionate	EMEA/H/C/004267Airexar Spiromax is indicated for use in adults aged 18 years and older only.AsthmaAirexar Spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist.Chronic Obstructive Pulmonary Disease (COPD)Airexar Spiromax is indicated for the symptomatic treatment of patients with COPD, with a FEV1	Withdrawn	no	no	no	2016-08-18

International Patents for ADVAIR HFA

See the table below for patents covering ADVAIR HFA around the world.

Country	Patent Number	Title	Estimated Expiration
Portugal	820323
Ireland	903256
Japan	5107976
Norway	974735

Supplementary Protection Certificates for ADVAIR HFA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2506844	1890025-8	Sweden		PRODUCT NAME: COMBINATION OF A PHARMACEUTICALLY ACCEPTABLE SALT OF UMECLIDINIUM (E.G. UMECLIDINIUM BROMIDE), VILANTEROL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF (E.G. VILANTEROL TRIFENATATE) AND FLUTICASONE FUROATE.; REG. NO/DATE: EU/1/17/1236 20171117
0416951	C990012	Netherlands		PRODUCT NAME: SALMETEROL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN FLUTICASONPROPIONAAT,IN HET BIJZONDER SALMETEROLXINAFOAAT EN FLUTICASONPROPIONAAT; NATL REGISTRATION NO/DATE: RVG 23529 - RVG 23534 19990112; FIRST REGISTRATION: SE 14591 - 14596 19980907
1519731	132013902182575	Italy		PRODUCT NAME: AZELASTINA CLORIDRATO/FLUTICASONE PROPIONATO(DYMISTA); AUTHORISATION NUMBER(S) AND DATE(S): 2011/07125-REG, 20111024;041808015/M-027/M-039/M-041/M, 20130527
2506844	132018000000341	Italy		PRODUCT NAME: UN PRODOTTO DI COMBINAZIONE FARMACEUTICA COMPRENDENTE UN SALE FARMACEUTICAMENTE ACCETTABILE DI UMECLIDINIO (AD ESEMPIO BROMURO DI UMECLIDINIO), VILANTEROLO O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE (AD ESEMPIO VILANTEROLO TRIFENATATO) E UN FUROATO(TRELEGY ELLIPTA - FLUTICASONE FUROATO/UMECLIDINIO/VILANTEROLO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1236, 20171117

ADVAIR HFA: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

ADVAIR HFA, a combination inhaler containing fluticasone propionate and salmeterol, generated approximately $1.9 billion in revenue in 2022. Its market performance is shaped by patent expirations, generic competition, and evolving treatment guidelines for asthma and chronic obstructive pulmonary disease (COPD).

What is the Current Market Position of ADVAIR HFA?

ADVAIR HFA, developed by GlaxoSmithKline (GSK), is a combination of an inhaled corticosteroid (ICS) and a long-acting beta-agonist (LABA). It is indicated for the treatment of asthma and COPD. The drug has been a significant revenue driver for GSK for many years.

The global market for respiratory inhalers is substantial, driven by the increasing prevalence of respiratory diseases worldwide. Asthma affects an estimated 262 million people globally, and COPD affects approximately 251 million people [1]. This large patient population underpins the demand for effective treatments like ADVAIR HFA.

However, the market for ADVAIR HFA is mature. Its primary U.S. patents expired in 2010, and its secondary patents expired thereafter, paving the way for generic competition [2]. This has led to a decline in its market share and revenue, as lower-cost generic alternatives become available.

What is the Patent Landscape for ADVAIR HFA?

The patent protection for ADVAIR HFA has significantly diminished, creating opportunities for generic manufacturers and impacting GSK's revenue streams.

• Composition of Matter Patents: The primary patent covering the specific combination of fluticasone propionate and salmeterol expired in 2010 in the U.S. [2]. This was the foundational patent that provided initial market exclusivity.

• Formulation and Method of Use Patents: GSK held numerous secondary patents related to the formulation of ADVAIR HFA, including the Diskus and HFA inhaler devices, as well as methods of use. These patents have also expired or are nearing expiration in various jurisdictions. For example, patents related to the Diskus device have expired, and similar expirations have occurred for the HFA formulation.

• Generic Entry: The expiration of key patents allowed generic versions of fluticasone propionate/salmeterol inhalation aerosol to enter the market. Companies such as Mylan (now Viatris) and Teva Pharmaceuticals have launched generic alternatives [3]. The U.S. Food and Drug Administration (FDA) has approved multiple generic versions, increasing competitive pressure.

• Patent Litigation: GSK has engaged in patent litigation to defend its intellectual property and delay generic entry. However, these efforts have had limited success in preventing the eventual market penetration of generics. The legal battles typically focus on specific patent claims related to manufacturing processes, delivery devices, or new indications.

The erosion of patent exclusivity directly correlates with the decline in ADVAIR HFA's market dominance and the shift in revenue towards generic manufacturers.

How Has Generic Competition Impacted ADVAIR HFA's Revenue?

The introduction of generic fluticasone propionate/salmeterol inhalation aerosol has had a substantial negative impact on ADVAIR HFA's revenue.

• Price Erosion: Generic drugs are typically priced at a significant discount compared to their branded counterparts. Once generics enter the market, they drive down the average selling price of the drug class. For ADVAIR HFA, this has resulted in a considerable reduction in revenue per unit sold.

• Market Share Loss: The availability of lower-cost generic options incentivizes payers, pharmacies, and physicians to switch to these alternatives. This leads to a direct loss of market share for the branded product. Surveys and market data consistently show a rapid decline in branded market share following generic entry.

• Revenue Decline Trends: GSK has reported significant revenue declines for ADVAIR. For instance, in 2017, ADVAIR sales were approximately $4.2 billion. By 2021, this figure had dropped to around $2.1 billion, and in 2022, it was approximately $1.9 billion, reflecting the ongoing impact of generic competition [4, 5]. This trend demonstrates a consistent erosion of revenue as the market transitions to generics.

• Impact on Profitability: While the gross profit margin on branded drugs is typically higher, the sheer volume of generic sales and the competitive pricing environment can significantly alter overall profitability. The decline in ADVAIR HFA's revenue has necessitated a strategic shift for GSK, focusing on newer products and therapeutic areas.

The financial trajectory of ADVAIR HFA is a textbook example of how patent expiration and generic competition can reshape the market for a once-dominant pharmaceutical.

What are the Key Market Drivers and Restraints for Respiratory Inhalers?

The broader market for respiratory inhalers, which includes ADVAIR HFA and its competitors, is influenced by several factors.

Market Drivers:

• Rising Prevalence of Respiratory Diseases: The increasing incidence of asthma and COPD globally, attributed to factors such as air pollution, aging populations, and lifestyle changes, fuels demand for inhaler therapies.

• Technological Advancements in Inhaler Devices: Innovations in inhaler technology, such as smart inhalers that track usage and improve adherence, and more efficient delivery systems, can drive market growth.

• Growing Awareness and Diagnosis: Increased patient and physician awareness of respiratory conditions leads to earlier diagnosis and initiation of treatment, expanding the patient pool for inhaler medications.

• Emergence of Biologics and Novel Therapies: While ADVAIR HFA is a conventional therapy, the development of biologics for severe asthma and other targeted therapies creates a complex treatment landscape, influencing prescribing patterns for older medications.

Market Restraints:

• Intensifying Generic Competition: As seen with ADVAIR HFA, the expiration of patents for established drugs leads to significant price reductions and market share erosion due to generic alternatives.

• Reimbursement Pressures and Payer Policies: Healthcare payers (insurance companies, government programs) exert pressure on drug pricing and often favor lower-cost generic options, limiting the market for branded products.

• Stringent Regulatory Approval Processes: While necessary for patient safety, the rigorous approval pathways for new drugs and complex device technologies can slow down market entry.

• Side Effects and Safety Concerns: Like all medications, ICS/LABA combinations can have side effects, and concerns about long-term safety profiles can influence prescribing decisions, especially with the availability of alternative treatment options.

These drivers and restraints collectively shape the competitive environment for respiratory inhaler products.

What is the Future Financial Outlook for ADVAIR HFA?

The financial outlook for ADVAIR HFA is characterized by continued revenue decline, driven primarily by ongoing generic competition and the strategic focus of its manufacturer.

• Continued Revenue Decline: GSK has explicitly stated its strategy to transition away from older, established products like ADVAIR HFA. Consequently, the drug's revenue is expected to continue its downward trajectory. Year-over-year declines are anticipated to persist as generic penetration increases across major markets.

• Market Share Erosion in Key Regions: In markets with established generic availability, such as the United States and Europe, ADVAIR HFA's market share has already been significantly compromised. Future market share will likely be minimal, confined to niche segments or specific patient populations that have not transitioned.

• Limited Investment in Lifecycle Management: With patent expirations and the focus on newer therapies, GSK is unlikely to make substantial investments in new clinical trials, line extensions, or significant marketing efforts for ADVAIR HFA. This limits its potential for resurgence.

• Transition to Newer GSK Products: GSK is actively promoting and investing in its next-generation respiratory portfolio, which includes products like Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) and other biologics for severe asthma. The company's financial reporting and strategic focus reflect this transition, with resources being redirected from legacy products.

• Potential for Residual Sales: While the overall trend is negative, residual sales will persist from patient inertia, physician preference for the branded product in certain cases, or geographical regions where generic availability is delayed. However, these sales will represent a small fraction of historical peak revenues.

The financial future of ADVAIR HFA is one of a mature product steadily exiting its peak revenue phase due to the inevitable impact of the pharmaceutical lifecycle.

Key Takeaways

• ADVAIR HFA’s revenue has declined significantly from its peak, driven by patent expirations and the subsequent entry of generic fluticasone propionate/salmeterol inhalation aerosol.
• The U.S. composition of matter patent for ADVAIR HFA expired in 2010, enabling generic manufacturers to launch lower-cost alternatives.
• Generic competition has led to substantial price erosion and loss of market share for ADVAIR HFA, with 2022 revenues approximating $1.9 billion.
• The broader respiratory inhaler market is influenced by the rising prevalence of respiratory diseases, technological advancements, and intense generic competition.
• The future financial outlook for ADVAIR HFA involves continued revenue decline as GSK focuses on newer respiratory products, rendering further significant growth unlikely.

Frequently Asked Questions

What is the primary reason for ADVAIR HFA's revenue decline?

The primary reason is the expiration of its core patents, which allowed generic versions of fluticasone propionate/salmeterol to enter the market, leading to price reductions and market share erosion.

Which companies are major competitors to ADVAIR HFA in the generic space?

Major competitors include Viatris (formerly Mylan) and Teva Pharmaceuticals, which have launched generic fluticasone propionate/salmeterol inhalation aerosol products.

What are the main therapeutic areas for which ADVAIR HFA is prescribed?

ADVAIR HFA is prescribed for the treatment of asthma and chronic obstructive pulmonary disease (COPD).

How has GSK managed the transition from ADVAIR HFA to newer products?

GSK is focusing its investment and marketing efforts on its next-generation respiratory portfolio, including Trelegy Ellipta and biologics for severe asthma, to capture market share and drive future revenue growth.

What is the typical market lifespan for a branded respiratory inhaler like ADVAIR HFA after patent expiration?

Following the expiration of primary patents, branded respiratory inhalers typically experience a rapid decline in market share and revenue over a period of 3-7 years as generic alternatives gain traction, though some residual sales may persist for longer.

Citations

[1] World Health Organization. (2023, May 12). Asthma. https://www.who.int/news-room/fact-sheets/detail/asthma [2] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.accessdata.fda.gov/scripts/cder/ob/ (Specific patent expiration dates are publicly searchable via the Orange Book database). [3] U.S. Food and Drug Administration. (2023, January 26). FDA approves first generic version of Advair Diskus. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-generic-version-advair-diskus (Note: This press release refers to Advair Diskus, but the patent landscape and generic entry dynamics are similar for the HFA formulation). [4] GlaxoSmithKline. (2018, February 7). GlaxoSmithKline plc Preliminary Results 2017. https://www.gsk.com/media/4815/gsk-preliminary-results-2017.pdf [5] GlaxoSmithKline. (2023, February 8). GlaxoSmithKline plc Full Year Results 2022. https://www.gsk.com/media/7516/gsk-full-year-results-2022.pdf